According to the Complaint, OvaScience is a life science company that engages in the discovery, development, and commercialization of new treatments for infertility. The Company develops various fertility treatment options purported to enhance egg health and revolutionize in vitro fertilization ("IVF"). The Company's AUGMENT treatment, designed to improve the energy and health of the woman's eggs by using mitochondria from a woman's egg precursor cells ("EggPCs"), is available in certain IVF clinics in select international regions.
The Complaint alleges that in violation of the Securities Act, Defendants negligently issued untrue statements
of material facts and omitted to state material facts required to be stated from the Registration Statement and incorporated Offering Materials that the Company filed with the SEC in support of the Offering.
On May 23, 2016, the Court issued an Order remanding this case to State Court.